Benign Breast Disease and Early Breast Cancer Market: Epidemiology, Therapies, Companies | DelveInsight | Key players in this space include Abbott Laboratories Inc., AbbVie Inc., Amgen Inc., Astellas

In the United States, Biopsy-confirmed benign breast disease diagnoses are four times more common than invasive Breast Cancers, affecting ~1 million women annually. There is lucrative potential to seize the marketplace of early-stage cancerous and benign breast disease because it is a broader indication and represents a greater population than an advanced disease.
Emerging therapies such as ECHOPULSE, ProSense, and others are expected to drive growth in the Benign Breast Disease and Early Breast Cancer market in the coming years.

DelveInsight has released a new report titled "Benign Breast Disease and Early Breast Cancer - Market Insights, Epidemiology, and Market Forecast 2034," providing a comprehensive analysis of the disease, including historical and projected epidemiology, as well as market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Discover about the Benign Breast Disease and Early Breast Cancer market report [https://www.delveinsight.com/report-store/benign-breast-disease-and-early-breast-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Some of the key facts of the Benign Breast Disease and Early Breast Cancer Market Report:

*
The Benign Breast Disease and Early Breast Cancer Market in the 7MM (US, EU4, UK, and Japan) is expected to grow at a notable compound annual growth rate (CAGR) over the 2020-2034 study period.

*
In September 2024, the U.S. Food and Drug Administration (FDA) approved Novartis' Kisqali (ribociclib) in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor-positive, HER2-negative (HR+/HER2) stage II and III early breast cancer at high risk of recurrence. This approval was based on the Phase III NATALEE trial, which showed that Kisqali reduced the risk of recurrence by 25% compared to endocrine therapy alone. The benefit was observed across all subgroups, including patients with node-negative disease.

*
In the United States, biopsy-confirmed benign breast disease is diagnosed approximately four times more frequently than invasive breast cancer, affecting around 1 million women annually. This highlights a substantial market opportunity, as early-stage and benign breast conditions impact a larger population than advanced breast cancer.

*
In 2023, the United States held the largest market share for benign and early breast cancer within the 7MM. In Europe, Germany led among the EU4 and UK, while Spain recorded the smallest share.

*
The COVID-19 pandemic significantly affected breast cancer care, leading to paused screening programs, delayed systemic treatments, and postponed surgeries, including reconstructive and preventive procedures.

*
Compared to breast cancer, there is a notable lack of clinical guidelines and research on the investigation and management of benign breast disease. For example, no standard imaging surveillance protocols exist for patients after mastectomy.

*
In 2023, the United States accounted for the highest number of new cases of benign breast disease and early breast cancer among the 7MM, representing roughly 49% of the total. That year, the U.S. reported around 1.4 million cases of benign breast disease and approximately 243,500 cases of early-stage breast cancer. The EU4 and the UK followed, with Japan contributing the smallest share.

*
Among benign breast conditions, fibroadenoma is the most commonly diagnosed subtype in the U.S., representing about 70% of all benign breast disease cases.

*
Key companies in the Benign Breast Disease and Early Breast Cancer market, including Abbott Laboratories Inc., AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca Plc, Biocon Ltd, Bristol-Myers Squibb Company, Eisai Inc., and others, are evaluating new therapies to enhance the treatment landscape.

*
Promising therapies in this space include ECHOPULSE, ProSense, and others.

Benign Breast Disease and Early Breast Cancer Overview

Benign breast disease includes a variety of non-cancerous breast lesions that are often identified through clinical examinations, imaging, self-exams, or symptoms such as breast pain (mastalgia). After confirmation of a benign diagnosis via imaging and, when necessary, biopsy, treatment generally focuses on symptom management and patient education, without requiring surgery. These conditions are more common in younger women, with incidence beginning in the teenage years and peaking between ages 40 and 50.

Early breast cancer refers to cancer that is limited to the breast and possibly nearby underarm lymph nodes, without spreading to other parts of the body. It generally includes Stage 0, Stage I, and Stage II breast cancers, as defined by the tumor staging system.

Benign Breast Disease and Early Breast Cancer Market Outlook

The current market is segmented according to commonly used treatment strategies across the 7MM, with minor variations in therapeutic practices. Surgical procedures, including lumpectomy, mastectomy, minimally invasive techniques, and excisional surgery for benign breast disease, represent the primary treatment options incorporated into the forecast model.

In 2023, the total market for Benign Breast Disease and Early Breast Cancer in the 7MM was estimated at approximately USD 8.8 billion and is projected to grow throughout the 2024-2034 forecast period. The United States held the largest market share at around 51%, followed by the EU4 and the UK, which together accounted for roughly 42% of the market.

Discover how the Benign Breast Disease and Early Breast Cancer market is rising in the coming years @ https://www.delveinsight.com/sample-request/benign-breast-disease-and-early-breast-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Benign Breast Disease and Early Breast Cancer Marketed Drugs

*
ECHOPULSE: Theraclion

*
ProSense: IceCure Medical

Scope of the Benign Breast Disease and Early Breast Cancer Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Benign Breast Disease and Early Breast Cancer Companies: Abbott Laboratories Inc., AbbVie Inc., Amgen Inc,, Astellas Pharma Inc., AstraZeneca Plc, Biocon Ltd, Bristol, Myers Squibb Company, Eisai Inc., and others

*
Benign Breast Disease and Early Breast Cancer Therapeutic Assessment: Benign Breast Disease and Early Breast Cancer current marketed and Benign Breast Disease and Early Breast Cancer emerging therapies

*
Benign Breast Disease and Early Breast Cancer Market Dynamics: Benign Breast Disease and Early Breast Cancer market drivers and Benign Breast Disease and Early Breast Cancer market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Benign Breast Disease and Early Breast Cancer Unmet Needs, KOL's views, Analyst's views, Benign Breast Disease and Early Breast Cancer Market Access and Reimbursement

To know what's more in our Benign Breast Disease and Early Breast Cancer report, visit https://www.delveinsight.com/report-store/benign-breast-disease-and-early-breast-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Key benefits of the Benign Breast Disease and Early Breast Cancer Market Report:

*
Benign Breast Disease and Early Breast Cancer market report covers a descriptive overview and comprehensive insight of the Benign Breast Disease and Early Breast Cancer Epidemiology and Benign Breast Disease and Early Breast Cancer market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).

*
The Benign Breast Disease and Early Breast Cancer market report provides insights into the current and emerging therapies.

*
The Benign Breast Disease and Early Breast Cancer market report provides a global historical and forecasted market covering drug outreach in 7MM.

*
The Benign Breast Disease and Early Breast Cancer market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Benign Breast Disease and Early Breast Cancer market.

Got queries? Click here to know more about the Benign Breast Disease and Early Breast Cancer market Landscape [https://www.delveinsight.com/sample-request/benign-breast-disease-and-early-breast-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Benign Breast Disease and Early Breast Cancer Patient Share (%) Overview at a Glance

5. Benign Breast Disease and Early Breast Cancer Market Overview at a Glance

6. Benign Breast Disease and Early Breast Cancer Disease Background and Overview

7. Benign Breast Disease and Early Breast Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Benign Breast Disease and Early Breast Cancer

9. Benign Breast Disease and Early Breast Cancer Current Treatment and Medical Practices

10. Unmet Needs

11. Benign Breast Disease and Early Breast Cancer Emerging Therapies

12. Benign Breast Disease and Early Breast Cancer Market Outlook

13. Country-Wise Benign Breast Disease and Early Breast Cancer Market Analysis (2020-2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Benign Breast Disease and Early Breast Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Benign Breast Disease and Early Breast Cancer Market Outlook 2034 [https://www.delveinsight.com/report-store/benign-breast-disease-and-early-breast-cancer-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Related Reports:

Benign Breast Disease and Early Breast Cancer Pipeline Insights, DelveInsight

"Benign Breast Disease and Early Breast Cancer Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Benign Breast Disease and Early Breast Cancer market. A detailed picture of the Benign Breast Disease and Early Breast Cancer pipeline landscape is provided, which includes the disease overview and Benign Breast Disease and Early Breast Cancer treatment guidelines.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=benign-breast-disease-and-early-breast-cancer-market-epidemiology-therapies-companies-delveinsight-key-players-in-this-space-include-abbott-laboratories-inc-abbvie-inc-amgen-inc-astellas]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.